Name change reflects company's leadership position with its cryptocurrency treasury reserve strategy focused on the HYPE token Company to commence trading on Nasdaq under the symbol "HYPD" effective July 3rd Also announces official launch of the Kinetiq x Hyperion validator LAGUNA HILLS, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) ("Eyenovia" or the "Company"), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, t ...

Core Insights - Eyenovia, Inc. is advancing its digital asset capital strategy by building a strategic treasury of HYPE, the native token of the Hyperliquid protocol [1][7] - Avenue Capital Group has become the largest common stockholder and has amended Eyenovia's senior secured debt to support the HYPE treasury, extending the maturity date to July 1, 2028, and reducing the interest rate from 12% to 8% [2] - Max Fiege has been appointed as Strategic Advisor to enhance the HYPE Treasury strategy, focusing on stakeholder education and ecosystem advocacy [4] Financial Developments - The amendment to the debt includes interest-only payments for the first 18 months, followed by equal principal and interest payments for the next 18 months [2] - The reduced interest rate and extended maturity are expected to provide financial flexibility as the company builds its HYPE treasury [2] Strategic Appointments - Max Fiege, with a background in blockchain and digital assets, will assist in the treasury architecture and risk oversight for Eyenovia [4][5] - His expertise is anticipated to enhance the company's position in the digital finance landscape [5] HYPE Token Overview - HYPE is the native token of the Hyperliquid layer one blockchain, allowing for non-custodial trading and offering utility such as trading fee discounts [6] - As of June 2025, HYPE ranks as the 12th-largest cryptocurrency by market capitalization [6] Company Overview - Eyenovia is a pioneering digital ophthalmic technology company, focusing on both innovative eye treatment solutions and building a treasury of HYPE [7] - The company is also developing the Optejet User Filled Device, targeting multiple billion-dollar markets in ophthalmic treatments [8]